Do analysts recommend OSRH or BJDX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OSR 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Bluejay Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is OSRH or BJDX more profitable?

Bluejay Diagnostics has a net margin of 0.00% compared to OSR's net margin of -363.26%. OSR's return on equity of -7.24% beat Bluejay Diagnostics' return on equity. Company Net Margins Return on Equity Return on Assets OSR -363.26% -7.24% -5.41% Bluejay Diagnostics N/A -144.27% -115.00%

Do analysts prefer BJDX or FEMY?

Femasys has a consensus price target of $106.67, indicating a potential upside of 2,752.05%. Given Femasys' stronger consensus rating and higher possible upside, analysts plainly believe Femasys is more favorable than Bluejay Diagnostics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bluejay Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Femasys 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Is BJDX or FEMY more profitable?

Bluejay Diagnostics has a net margin of 0.00% compared to Femasys' net margin of -521.97%. Bluejay Diagnostics' return on equity of -144.27% beat Femasys' return on equity. Company Net Margins Return on Equity Return on Assets Bluejay Diagnostics N/A -144.27% -115.00% Femasys -521.97% -258.08% -73.72%

Do analysts prefer BJDX or SURG?

SurgePays has a consensus target price of $3.50, indicating a potential upside of 926.39%. Given SurgePays' stronger consensus rating and higher probable upside, analysts clearly believe SurgePays is more favorable than Bluejay Diagnostics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bluejay Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 SurgePays 2 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is BJDX or SURG more profitable?

Bluejay Diagnostics has a net margin of 0.00% compared to SurgePays' net margin of -64.91%. Bluejay Diagnostics' return on equity of -144.27% beat SurgePays' return on equity. Company Net Margins Return on Equity Return on Assets Bluejay Diagnostics N/A -144.27% -115.00% SurgePays -64.91% -967.32% -310.16%

Do analysts recommend MBAI or BJDX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Check-Cap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Bluejay Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, MBAI or BJDX?

Check-Cap is trading at a lower price-to-earnings ratio than Bluejay Diagnostics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Check-Cap N/A N/A $4.14M -$2.77 N/A Bluejay Diagnostics N/A N/A -$6.85M -$11.63 N/A

Is MBAI or BJDX more profitable?

Check-Cap's return on equity of 0.00% beat Bluejay Diagnostics' return on equity. Company Net Margins Return on Equity Return on Assets Check-Cap N/A N/A N/A Bluejay Diagnostics N/A -144.27% -115.00%

Do analysts recommend BJDX or ALUR?

Allurion Technologies has a consensus price target of $45.00, suggesting a potential upside of 7,658.62%. Given Allurion Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Allurion Technologies is more favorable than Bluejay Diagnostics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bluejay Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Allurion Technologies 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Bluejay Diagnostics (BJDX) Competitors

$1.44 -1.49 (-50.85%)

Closing price 06/29/2026 04:00 PM Eastern

Extended Trading

$1.28 -0.16 (-11.39%)

As of 05:27 AM Eastern

Compare

BJDX vs. OSRH, FEMY, SURG, MBAI, and ALUR

Should you buy Bluejay Diagnostics stock or one of its competitors? MarketBeat compares Bluejay Diagnostics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bluejay Diagnostics include OSR (OSRH), Femasys (FEMY), SurgePays (SURG), Check-Cap (MBAI), and Allurion Technologies (ALUR). These companies are all part of the "medical equipment" industry.

How does Bluejay Diagnostics compare to OSR?

OSR (NASDAQ:OSRH) and Bluejay Diagnostics (NASDAQ:BJDX) are both small-cap medical equipment companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

In the previous week, OSR and OSR both had 2 articles in the media. OSR's average media sentiment score of 0.62 beat Bluejay Diagnostics' score of 0.44 indicating that OSR is being referred to more favorably in the media.

Company	Overall Sentiment
OSR	Positive
Bluejay Diagnostics	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OSR	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Bluejay Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Bluejay Diagnostics has a net margin of 0.00% compared to OSR's net margin of -363.26%. OSR's return on equity of -7.24% beat Bluejay Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OSR	-363.26%	-7.24%	-5.41%
Bluejay Diagnostics	N/A	-144.27%	-115.00%

55.3% of OSR shares are owned by institutional investors. Comparatively, 18.5% of Bluejay Diagnostics shares are owned by institutional investors. 36.8% of OSR shares are owned by company insiders. Comparatively, 6.1% of Bluejay Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Bluejay Diagnostics has lower revenue, but higher earnings than OSR. OSR is trading at a lower price-to-earnings ratio than Bluejay Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OSR	$2.91M	3.87	-$27.06M	-$0.33	N/A
Bluejay Diagnostics	N/A	N/A	-$6.85M	-$11.63	N/A

OSR has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market. Comparatively, Bluejay Diagnostics has a beta of 0.82, meaning that its share price is 18% less volatile than the broader market.

Summary

OSR beats Bluejay Diagnostics on 7 of the 11 factors compared between the two stocks.

How does Bluejay Diagnostics compare to Femasys?

Bluejay Diagnostics (NASDAQ:BJDX) and Femasys (NASDAQ:FEMY) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, dividends, risk and analyst recommendations.

Femasys has a consensus price target of $106.67, indicating a potential upside of 2,752.05%. Given Femasys' stronger consensus rating and higher possible upside, analysts plainly believe Femasys is more favorable than Bluejay Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bluejay Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Bluejay Diagnostics has a beta of 0.82, meaning that its share price is 18% less volatile than the broader market. Comparatively, Femasys has a beta of -2.23, meaning that its share price is 323% less volatile than the broader market.

In the previous week, Femasys had 4 more articles in the media than Bluejay Diagnostics. MarketBeat recorded 6 mentions for Femasys and 2 mentions for Bluejay Diagnostics. Femasys' average media sentiment score of 0.64 beat Bluejay Diagnostics' score of 0.44 indicating that Femasys is being referred to more favorably in the news media.

Company	Overall Sentiment
Bluejay Diagnostics	Neutral
Femasys	Positive

Bluejay Diagnostics has a net margin of 0.00% compared to Femasys' net margin of -521.97%. Bluejay Diagnostics' return on equity of -144.27% beat Femasys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bluejay Diagnostics	N/A	-144.27%	-115.00%
Femasys	-521.97%	-258.08%	-73.72%

18.5% of Bluejay Diagnostics shares are held by institutional investors. Comparatively, 65.3% of Femasys shares are held by institutional investors. 6.1% of Bluejay Diagnostics shares are held by company insiders. Comparatively, 7.8% of Femasys shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Bluejay Diagnostics has higher earnings, but lower revenue than Femasys. Femasys is trading at a lower price-to-earnings ratio than Bluejay Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bluejay Diagnostics	N/A	N/A	-$6.85M	-$11.63	N/A
Femasys	$2.29M	4.93	-$18.63M	-$5.40	N/A

Summary

Femasys beats Bluejay Diagnostics on 10 of the 15 factors compared between the two stocks.

How does Bluejay Diagnostics compare to SurgePays?

Bluejay Diagnostics (NASDAQ:BJDX) and SurgePays (NASDAQ:SURG) are both small-cap medical equipment companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

In the previous week, Bluejay Diagnostics had 1 more articles in the media than SurgePays. MarketBeat recorded 2 mentions for Bluejay Diagnostics and 1 mentions for SurgePays. SurgePays' average media sentiment score of 1.87 beat Bluejay Diagnostics' score of 0.44 indicating that SurgePays is being referred to more favorably in the news media.

Company	Overall Sentiment
Bluejay Diagnostics	Neutral
SurgePays	Very Positive

Bluejay Diagnostics has a beta of 0.82, meaning that its stock price is 18% less volatile than the broader market. Comparatively, SurgePays has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market.

Bluejay Diagnostics has a net margin of 0.00% compared to SurgePays' net margin of -64.91%. Bluejay Diagnostics' return on equity of -144.27% beat SurgePays' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bluejay Diagnostics	N/A	-144.27%	-115.00%
SurgePays	-64.91%	-967.32%	-310.16%

SurgePays has a consensus target price of $3.50, indicating a potential upside of 926.39%. Given SurgePays' stronger consensus rating and higher probable upside, analysts clearly believe SurgePays is more favorable than Bluejay Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bluejay Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
SurgePays	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

Bluejay Diagnostics has higher earnings, but lower revenue than SurgePays. SurgePays is trading at a lower price-to-earnings ratio than Bluejay Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bluejay Diagnostics	N/A	N/A	-$6.85M	-$11.63	N/A
SurgePays	$56.96M	0.15	-$36.07M	-$1.94	N/A

18.5% of Bluejay Diagnostics shares are owned by institutional investors. Comparatively, 6.9% of SurgePays shares are owned by institutional investors. 6.1% of Bluejay Diagnostics shares are owned by company insiders. Comparatively, 29.1% of SurgePays shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Bluejay Diagnostics beats SurgePays on 8 of the 15 factors compared between the two stocks.

How does Bluejay Diagnostics compare to Check-Cap?

Check-Cap (NASDAQ:MBAI) and Bluejay Diagnostics (NASDAQ:BJDX) are both small-cap medical equipment companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings, risk and media sentiment.

In the previous week, Check-Cap had 1 more articles in the media than Bluejay Diagnostics. MarketBeat recorded 3 mentions for Check-Cap and 2 mentions for Bluejay Diagnostics. Bluejay Diagnostics' average media sentiment score of 0.44 beat Check-Cap's score of 0.36 indicating that Bluejay Diagnostics is being referred to more favorably in the news media.

Company	Overall Sentiment
Check-Cap	Neutral
Bluejay Diagnostics	Neutral

Check-Cap's return on equity of 0.00% beat Bluejay Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Check-Cap	N/A	N/A	N/A
Bluejay Diagnostics	N/A	-144.27%	-115.00%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Check-Cap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Bluejay Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

1.1% of Check-Cap shares are owned by institutional investors. Comparatively, 18.5% of Bluejay Diagnostics shares are owned by institutional investors. 0.5% of Check-Cap shares are owned by insiders. Comparatively, 6.1% of Bluejay Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Check-Cap is trading at a lower price-to-earnings ratio than Bluejay Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Check-Cap	N/A	N/A	$4.14M	-$2.77	N/A
Bluejay Diagnostics	N/A	N/A	-$6.85M	-$11.63	N/A

Check-Cap has a beta of 0.59, suggesting that its stock price is 41% less volatile than the broader market. Comparatively, Bluejay Diagnostics has a beta of 0.82, suggesting that its stock price is 18% less volatile than the broader market.

Summary

Check-Cap and Bluejay Diagnostics tied by winning 5 of the 10 factors compared between the two stocks.

How does Bluejay Diagnostics compare to Allurion Technologies?

Bluejay Diagnostics (NASDAQ:BJDX) and Allurion Technologies (NYSE:ALUR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership and earnings.

Allurion Technologies has a consensus price target of $45.00, suggesting a potential upside of 7,658.62%. Given Allurion Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Allurion Technologies is more favorable than Bluejay Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bluejay Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Allurion Technologies	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Bluejay Diagnostics had 2 more articles in the media than Allurion Technologies. MarketBeat recorded 2 mentions for Bluejay Diagnostics and 0 mentions for Allurion Technologies. Bluejay Diagnostics' average media sentiment score of 0.44 beat Allurion Technologies' score of 0.00 indicating that Bluejay Diagnostics is being referred to more favorably in the media.

Company	Overall Sentiment
Bluejay Diagnostics	Neutral
Allurion Technologies	Neutral

Bluejay Diagnostics has a net margin of 0.00% compared to Allurion Technologies' net margin of -199.96%. Allurion Technologies' return on equity of 0.00% beat Bluejay Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bluejay Diagnostics	N/A	-144.27%	-115.00%
Allurion Technologies	-199.96%	N/A	-77.13%

Bluejay Diagnostics has higher earnings, but lower revenue than Allurion Technologies. Allurion Technologies is trading at a lower price-to-earnings ratio than Bluejay Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bluejay Diagnostics	N/A	N/A	-$6.85M	-$11.63	N/A
Allurion Technologies	$17.21M	0.51	-$7.20M	-$2.03	N/A

Bluejay Diagnostics has a beta of 0.82, indicating that its stock price is 18% less volatile than the broader market. Comparatively, Allurion Technologies has a beta of -0.13, indicating that its stock price is 113% less volatile than the broader market.

18.5% of Bluejay Diagnostics shares are owned by institutional investors. Comparatively, 21.4% of Allurion Technologies shares are owned by institutional investors. 6.1% of Bluejay Diagnostics shares are owned by company insiders. Comparatively, 8.1% of Allurion Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Allurion Technologies beats Bluejay Diagnostics on 10 of the 15 factors compared between the two stocks.

Get Bluejay Diagnostics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BJDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BJDX vs. The Competition

Export

Metric	Bluejay Diagnostics	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.03M	$7.36B	$6.84B	$12.20B
Dividend Yield	N/A	1.24%	2.66%	6.22%
P/E Ratio	-0.12	51.01	26.04	24.37
Price / Sales	N/A	83.89	547.53	100.48
Price / Cash	N/A	26.99	29.09	36.93
Price / Book	0.17	7.63	10.97	6.49
Net Income	-$6.85M	$159.19M	$3.57B	$336.61M
7 Day Performance	-62.89%	2.17%	2.50%	1.20%
1 Month Performance	-32.71%	-3.34%	0.86%	0.20%
1 Year Performance	-79.07%	6.03%	36.40%	30.15%

Bluejay Diagnostics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BJDX Bluejay Diagnostics	0.3376 of 5 stars	$1.44 -50.9%	N/A	-77.8%	$3.03M	N/A	N/A	9
OSRH OSR	0.6466 of 5 stars	$0.35 -3.6%	N/A	-76.2%	$12.29M	$2.63M	N/A	N/A
FEMY Femasys	2.5615 of 5 stars	$3.93 -1.9%	$106.67 +2,612.1%	-80.9%	$11.87M	$2.38M	N/A	30
SURG SurgePays	3.8371 of 5 stars	$0.41 +2.6%	$3.50 +760.0%	-89.3%	$10.23M	$62.37M	N/A	40	Positive News
MBAI Check-Cap	0.2383 of 5 stars	$1.33 -2.2%	N/A	N/A	$9.70M	N/A	N/A	80	News Coverage Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BJDX) was last updated on 6/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bluejay Diagnostics (BJDX) Competitors

BJDX vs. OSRH, FEMY, SURG, MBAI, and ALUR

How does Bluejay Diagnostics compare to OSR?

Summary

How does Bluejay Diagnostics compare to Femasys?

Summary

How does Bluejay Diagnostics compare to SurgePays?

Summary

How does Bluejay Diagnostics compare to Check-Cap?

Summary

How does Bluejay Diagnostics compare to Allurion Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BJDX vs. The Competition

Bluejay Diagnostics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bluejay Diagnostics (BJDX) Competitors

BJDX vs. OSRH, FEMY, SURG, MBAI, and ALUR

How does Bluejay Diagnostics compare to OSR?

Does the media refer more to OSRH or BJDX?

Do analysts recommend OSRH or BJDX?

Is OSRH or BJDX more profitable?

Do insiders and institutionals hold more shares of OSRH or BJDX?

Which has higher earnings and valuation, OSRH or BJDX?

Which has more risk and volatility, OSRH or BJDX?

Summary

How does Bluejay Diagnostics compare to Femasys?

Do analysts prefer BJDX or FEMY?

Which has more risk and volatility, BJDX or FEMY?

Does the media prefer BJDX or FEMY?

Is BJDX or FEMY more profitable?

Do insiders & institutionals have more ownership in BJDX or FEMY?

Which has stronger earnings & valuation, BJDX or FEMY?

Summary

How does Bluejay Diagnostics compare to SurgePays?

Does the media prefer BJDX or SURG?

Which has more volatility and risk, BJDX or SURG?

Is BJDX or SURG more profitable?

Do analysts prefer BJDX or SURG?

Which has better valuation & earnings, BJDX or SURG?

Do insiders and institutionals have more ownership in BJDX or SURG?

Summary

How does Bluejay Diagnostics compare to Check-Cap?

Does the media favor MBAI or BJDX?

Is MBAI or BJDX more profitable?

Do analysts recommend MBAI or BJDX?

Do institutionals & insiders have more ownership in MBAI or BJDX?

Which has preferable valuation & earnings, MBAI or BJDX?

Which has more risk and volatility, MBAI or BJDX?

Summary

How does Bluejay Diagnostics compare to Allurion Technologies?

Do analysts recommend BJDX or ALUR?

Does the media prefer BJDX or ALUR?

Is BJDX or ALUR more profitable?

Which has preferable earnings & valuation, BJDX or ALUR?

Which has more volatility & risk, BJDX or ALUR?

Do insiders and institutionals hold more shares of BJDX or ALUR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BJDX vs. The Competition

Bluejay Diagnostics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools